.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
McKinsey
Colorcon
Accenture
US Army
Mallinckrodt
Moodys
Express Scripts
Queensland Health
Julphar

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,829,595

« Back to Dashboard

Which drugs does patent 7,829,595 protect, and when does it expire?


Patent 7,829,595 protects SENSIPAR and is included in one NDA. There has been one Paragraph IV challenge on Sensipar.

This patent has thirty-three patent family members in twenty-five countries.

Summary for Patent: 7,829,595

Title:Rapid dissolution formulation of a calcium receptor-active compound
Abstract:The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, wherein the composition has a controlled dissolution profile. The present invention further relates to a method of manufacturing the pharmaceutical composition, as well as a method of treating a disease using the pharmaceutical composition.
Inventor(s): Lawrence; Glen Gary (Thousand Oaks, CA), Alvarez; Francisco J. (Newbury Park, CA), Lin; Hung-Ren H. (Oak Park, CA), Ju; Tzuchi R. (Vernon Hills, IL)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Application Number:10/937,870
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
AmgenSENSIPARcinacalcet hydrochlorideTABLET;ORAL021688-001Mar 8, 2004RXYesNo► Subscribe► Subscribe► SubscribeYMETHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
AmgenSENSIPARcinacalcet hydrochlorideTABLET;ORAL021688-002Mar 8, 2004RXYesNo► Subscribe► Subscribe► SubscribeYMETHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
AmgenSENSIPARcinacalcet hydrochlorideTABLET;ORAL021688-003Mar 8, 2004RXYesYes► Subscribe► Subscribe► SubscribeYMETHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,829,595

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,375,405Rapid dissolution formulation of a calcium receptor-active compound► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,829,595

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China1946382► Subscribe
Cyprus1113703► Subscribe
Denmark1663182► Subscribe
Eurasian Patent Organization200600566► Subscribe
Eurasian Patent Organization013425► Subscribe
Israel173737► Subscribe
European Patent Office1663182► Subscribe
European Patent Office2316442► Subscribe
European Patent Office2821067► Subscribe
Spain2401769► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Boehringer Ingelheim
Cantor Fitzgerald
Harvard Business School
Chubb
Chinese Patent Office
Fish and Richardson
US Department of Justice
Baxter
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot